Open AccessEvaluation of Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Patients With COVID-19 and Non-COVID-19 Pneumonia: An Observational Cohort Study
Author(s) -
Dimitrios Velissaris,
Maria Lagadinou,
Themistoklis Paraskevas,
Eleousa Oikonomou,
Vasileios Karamouzos,
Sofia Karteri,
Dimitrios Bousis,
Nikolaos Pantzaris,
Konstantinos Tsiotsios,
Markos Marangos
Publication year - 2021
Publication title -
journal of clinical medicine research
Language(s) - English
Resource type - Journals
eISSN - 1918-3011
pISSN - 1918-3003
DOI - 10.14740/jocmr4579
Subject(s) - supar , medicine , pneumonia , fraction of inspired oxygen , biomarker , covid-19 , cohort , gastroenterology , urokinase receptor , urokinase , immunology , disease , infectious disease (medical specialty) , mechanical ventilation , biochemistry , chemistry
The respiratory system is the main system affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a great number of infected people need hospitalization. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker indicative of acute and chronic inflammation. Current literature supports that suPAR has great predictive ability for mortality in patients with coronavirus disease 2019 (COVID-19). The aim of this study was to compare the value of suPAR and other laboratory biomarkers in patients with chest infection and suspected COVID-19.